Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DWTX
stocks logo

DWTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast DWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DWTX is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast DWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DWTX is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.140
sliders
Low
12.00
Averages
21.00
High
30.00
Current: 6.140
sliders
Low
12.00
Averages
21.00
High
30.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$10 -> $12
2025-09-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $12
2025-09-30
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Dogwood to $12 from $10 and keeps a Buy rating on the shares after the company announced a new licensing agreement with Serpin Pharma.
HC Wainwright & Co.
Sean Lee
Hold
to
Strong Buy
Upgrades
$10
2025-04-23
Reason
HC Wainwright & Co.
Sean Lee
Price Target
$10
2025-04-23
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dogwood Therapeutics Inc (DWTX.O) is -2.20, compared to its 5-year average forward P/E of -2.15. For a more detailed relative valuation and DCF analysis to assess Dogwood Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.15
Current PE
-2.20
Overvalued PE
-0.76
Undervalued PE
-3.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DWTX News & Events

Events Timeline

(ET)
2025-12-02
08:30:00
Dogwood Therapeutics Files for IP Protection of Synthetic Halneuron Until 2045
select
2025-11-11 (ET)
2025-11-11
08:52:38
Dogwood registers initial 100 participants in Halneuron Phase 2b study
select
2025-11-06 (ET)
2025-11-06
08:46:43
Dogwood announces Q3 earnings per share of $8.20, compared to a loss of $2.05 in the previous year.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-12Yahoo Finance
Dogwood Therapeutics Registers 100 Participants in Halneuron Study for Chemotherapy-Induced Pain

  • Study Enrollment: Dogwood Therapeutics (DWTX) has successfully enrolled the first 100 patients in its Phase 2b clinical study for Halneur.

  • Clinical Focus: The study aims to evaluate the efficacy and safety of Halneur in treating specific medical conditions.

[object Object]
Preview
7.5
09-29Newsfilter
Dogwood Therapeutics Obtains Exclusive Global, Royalty-Free License for SP16 Development and Commercialization as a Cancer Pain Treatment in All-Stock Deal Highlighting Commitment to Enhancing Cancer Patient Care

  • SP16 Phase 1b Study Announcement: Dogwood Therapeutics has announced a fully funded Phase 1b study for SP16, a first-in-class LRP1 agonist aimed at treating chemotherapy-induced peripheral neuropathy (CIPN), with patient enrollment expected to start in the first half of 2026.

  • Licensing Agreement with Serpin Pharma: The company secured a royalty-free global license to develop Serpin Pharma's intravenous formulation of SP16 for managing cancer-related pain, complementing its lead candidate Halneuron®, which is currently in Phase 2b development for chemotherapy-induced neuropathic pain.

[object Object]
Preview
7.5
09-29NASDAQ.COM
Dogwood Obtains License to Develop Serpin Pharma's SP16 IV Formulation

  • Dogwood Therapeutics License Agreement: Dogwood Therapeutics has acquired a royalty-free, global license from Serpin Pharma to develop an intravenous formulation of SP16 for managing cancer-related pain and chemotherapy-induced neuropathy symptoms through an all-stock transaction.

  • Equity Compensation Details: As part of the licensing agreement, Serpin Pharma will receive 382,034 shares of Dogwood's common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, totaling 7.31% of Dogwood's common stock on a fully diluted basis.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dogwood Therapeutics Inc (DWTX) stock price today?

The current price of DWTX is 6.14 USD — it has decreased -1.13 % in the last trading day.

arrow icon

What is Dogwood Therapeutics Inc (DWTX)'s business?

Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).

arrow icon

What is the price predicton of DWTX Stock?

Wall Street analysts forecast DWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DWTX is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dogwood Therapeutics Inc (DWTX)'s revenue for the last quarter?

Dogwood Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Dogwood Therapeutics Inc (DWTX)'s earnings per share (EPS) for the last quarter?

Dogwood Therapeutics Inc. EPS for the last quarter amounts to -8.20 USD, decreased -84.03 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dogwood Therapeutics Inc (DWTX)'s fundamentals?

The market is revising No Change the revenue expectations for Dogwood Therapeutics, Inc. (DWTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 25.31%.
arrow icon

How many employees does Dogwood Therapeutics Inc (DWTX). have?

Dogwood Therapeutics Inc (DWTX) has 12 emplpoyees as of December 05 2025.

arrow icon

What is Dogwood Therapeutics Inc (DWTX) market cap?

Today DWTX has the market capitalization of 182.53M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free